Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer - Contacts and Locations

Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer

This study is currently recruiting participants.

Study NCT00691730. Last updated on August 6, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00691730

Locations


Canada, Alberta
	Tom Baker Cancer Centre - Calgary	Recruiting
	Calgary, Alberta, Canada, T2N 4N2
	Contact: Patricia Tang 403-521-3707

Canada, Ontario
	Mount Sinai Hospital - Toronto	Recruiting
	Toronto, Ontario, Canada, M5G 1X5
	Contact: Susan Quaggin 416-586-4800
	Princess Margaret Hospital	Recruiting
	Toronto, Ontario, Canada, M5G 2M9
	Contact: Malcolm J. Moore, MD 416-946-2263

Sponsors and Collaborators

Princess Margaret Hospital, Canada

National Cancer Institute (NCI)

Investigators


Study Chair:	Malcolm J. Moore, MD	Princess Margaret Hospital, Canada